Immunocore Holdings plc (IMCR) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $138.00K; Additional Paid in CapitalUSD $1.27B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-34.33M; Retained Earnings (Accumulated Deficit)USD $-819.11M.
- 2026-03-31: Common Stock, Value, IssuedUSD $137.00K; Additional Paid in CapitalUSD $1.25B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-35.37M; Retained Earnings (Accumulated Deficit)USD $-818.30M.
- 2025-12-31: Common Stock, Value, IssuedUSD $136.00K; Additional Paid in CapitalUSD $1.24B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-28.08M; Retained Earnings (Accumulated Deficit)USD $-831.27M.
- 2025-09-30: Common Stock, Value, IssuedUSD $135.00K; Additional Paid in CapitalUSD $1.23B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-30.01M; Retained Earnings (Accumulated Deficit)USD $-801.22M.
Immunocore Holdings plc Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | Retained Earnings GBP |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $138.00K | $1.27B | $-34.33M | $-819.11M | $419.80M | 3 month · $9.40M | (m) |
| 2026-03-31 | $137.00K | $1.25B | $-35.37M | $-818.30M | $393.67M | 3 month · $6.30M | (m) |
| 2025-12-31 | $136.00K | $1.24B | $-28.08M | $-831.27M | $381.03M | 12 month · $37.78M | (m) |
| 2025-09-30 | $135.00K | $1.23B | $-30.01M | $-801.22M | $396.56M | 3 month · $9.79M | (m) |
| 2025-06-30 | $135.00K | $1.22B | $-26.61M | $-801.04M | $388.48M | 3 month · $10.16M | (m) |
| 2025-03-31 | $135.00K | $1.20B | $-33.09M | $-790.74M | $378.48M | 3 month · $9.52M | (m) |
| 2024-12-31 | $135.00K | $1.19B | $-33.76M | $-795.76M | $360.72M | 12 month · $34.20M | (m) |
| 2024-09-30 | $135.00K | $1.18B | $-31.17M | $-771.99M | $377.83M | 3 month · $6.51M | (m) |
| 2024-06-30 | $135.00K | $1.17B | $-34.42M | $-780.73M | $359.14M | 3 month · $9.98M 6 month · $19.00M | (m) |
| 2024-03-31 | $135.00K | $1.16B | $-35.36M | $-769.11M | $359.53M | 3 month · $9.02M | (m) |
| 2023-12-31 | $134.00K | $1.15B | $-36.26M | $-744.67M | $368.84M | 12 month · $32.47M | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | $355.97M | 3 month · $8.20M | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | $351.44M | 3 month · $8.82M 6 month · $17.08M | -292.03M |
| 2023-03-31 | (m) | (m) | (m) | (m) | $341.30M | 3 month · $8.26M | (m) |
| 2022-12-31 | $129.00K | $1.08B | $-54.67M | $-689.39M | $338.90M | 12 month · $32.89M | -261.25M |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | -236.05M |
| 2021-12-31 | (m) | (m) | (m) | (m) | $233.71M | 12 month · $48.89M | -481.39M |
| 2020-12-31 | (m) | (m) | (m) | (m) | $76.91M | (m) | -349.87M |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | -279.11M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |